CEO & Founder, McBrinn Management Consulting
Sylvia McBrinn has more than 25 years of executive management experience in the pharmaceutical and biotech industries. She currently serves on the Board of Directors of Axerion Therapeutics, Inc, a private, early stage biotech company and on the Advisory Board of Rebiotix.
From 2009 to 2012, Sylvia was the CEO, President and co-founder of Axerion Therapeutics. In this position, Ms. McBrinn raised seed and significant non-dilutive funding and secured a partnership with Astra Zeneca for one of Axerion’s key programs. She is the founder of McBrinn Management Consultants, LLC, providing counsel to biotech and pharmaceutical companies on strategy, business development, commercialization and start up related challenges.
From 2005 to 2008, Ms. McBrinn was the head of the US subsidiary of Vernalis, a British Biotech company where she was responsible for establishing and growing all business operations functions at the company from launch to 50 employees, as well as, leading a co-promotion effort and licensing a Neurology product. Her experience culminated in the sale of the US division to Ipsen Pharmaceuticals providing them with a turnkey neurology commercial organization.
From the beginning of her career through 2003, Ms. McBrinn held numerous positions of increasing responsibility in sales and marketing management at Pharmacia (until it’s acquisition by Pfizer), including positions as Global VP of Marketing for both blockbuster and specialty products. Ms. McBrinn has significant experience in the commercialization and launch of biotech and pharmaceutical products, business development, strategic planning and general management.
Ms. McBrinn earned her undergraduate degree in Biology from DeSales University and holds an MBA in Marketing from Widener University.